| Recruiting | A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Enc Epileptic Encephalopathy | Phase 1 / Phase 2 | 2025-11-24 |
| Withdrawn | S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastat Esophageal Squamous Cell Carcinoma | Phase 1 / Phase 2 | 2025-05-01 |
| Active Not Recruiting | Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma IDH1-mutant Glioma, IDH2-mutant Glioma | Phase 1 / Phase 2 | 2025-01-22 |
| Recruiting | Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanc Locally Advanced, Unresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation | Phase 1 / Phase 2 | 2024-12-16 |
| Recruiting | Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Na Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS) | Phase 3 | 2024-12-03 |
| Active Not Recruiting | Phase 2 Study of Irinotecan Liposome Injection, Oxaliplatin, 5-fluorouracil/Levoleucovorin in Japanese Partici Metastatic Adenocarcinoma of the Pancreas | Phase 2 | 2024-04-25 |
| Recruiting | Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis | Phase 1 / Phase 2 | 2023-04-18 |
| Completed | A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Hepatic Impairment | Phase 1 | 2023-03-14 |
| Active Not Recruiting | Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma Astrocytoma, Oligodendroglioma | Phase 1 | 2023-01-20 |
| Terminated | Immuno-positron Emission Tomography Study of 89Zr-S095012 in Patients With Advanced Solid Tumours Advanced Solid Tumor | Phase 1 | 2022-11-21 |
| Terminated | Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiraci Metastatic Colorectal Cancer | Phase 3 | 2022-04-21 |
| Active Not Recruiting | S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Follo Solid Tumor | Phase 1 | 2021-10-15 |
| Terminated | Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arteria Dyslipidemias, Hypertension | Phase 3 | 2021-09-09 |
| Completed | Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients Primary Sjögren's Syndrome | Phase 2 | 2021-08-03 |
| Terminated | SPARK-ALL: Calaspargase Pegol in Adults With ALL Acute Lymphoblastic Leukemia | Phase 2 / Phase 3 | 2021-07-07 |
| Withdrawn | Clinical Investigation to Determine the Accuracy and Benefit of Cardioskin™ in Patients With Known Atrial Fibr Atrial Fibrillation | N/A | 2021-07-01 |
| Completed | A Roll-over Study to Provide Continued Treatment With Lyophilized Pegaspargase (S95014) in Pediatric Patients Acute Lymphoblastic Leukemia | Phase 2 | 2021-06-15 |
| Completed | A Study Comparing the Blood Levels of Both Pegaspargase (S95014) Formulations (Liquid vs Lyophilized) in the T Acute Lymphoblastic Leukemia | Phase 2 | 2021-05-07 |
| Active Not Recruiting | A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Advanced Lymphoid Leukemia | Phase 1 | 2021-03-10 |
| Active Not Recruiting | Phase I/II Trial of S65487 Plus Azacitidine in Acute Myeloid Leukemia Acute Myeloid Leukemia | Phase 1 / Phase 2 | 2021-03-10 |
| Completed | Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia Acute Myeloid Leukaemia | Phase 1 / Phase 2 | 2021-02-17 |
| Active Not Recruiting | Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 M Grade 2 Glioma, Residual Glioma, Recurrent Glioma | Phase 3 | 2020-01-05 |
| Completed | A Clinical Study of SHP674 (Pegaspargase) in Participants With Newly Diagnosed, Untreated Acute Lymphoblastic Acute Lymphoblastic Leukemia | Phase 2 | 2019-10-17 |
| Terminated | Study of a New Intravenous Drug, Called S65487, in Patients With Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Relapsed or Refractory Acute Myeloid Leukemia, Relapsed or Refractory Non-Hodgkin Lymphoma, Relapsed or Refractory Multiple Myeloma | Phase 1 | 2019-07-17 |
| Completed | Efficacy and Safety of Perindopril 5 mg / Indapamide 1.25 mg / Amlodipine 5 mg Fixed Combination in Hypertensi Hypertension | Phase 3 | 2019-05-06 |
| Active Not Recruiting | Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate fo Metastatic Colorectal Cancer | Phase 3 | 2019-03-21 |
| Completed | Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Ven Acute Myeloid Leukaemia | Phase 1 | 2018-11-28 |
| Terminated | Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old Wit Autism Spectrum Disorder (ASD) | Phase 3 | 2018-10-04 |
| Terminated | Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children and Adolescents Aged From 7 to Less Than Autism Spectrum Disorder (ASD) | Phase 3 | 2018-09-24 |
| Completed | Study of AG-120 and AG-881 in Subjects With Low Grade Glioma Glioma | Phase 1 | 2018-03-20 |
| Completed | Post Marketing Surveillance Study for ONIVYDE® in South Korea Metastatic Pancreatic Cancer | — | 2018-03-08 |
| Terminated | Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss Advanced Solid Tumors, Lymphoma | Phase 1 | 2018-03-04 |
| Completed | Safety of Single Intravenous Administration of S95010 in Human Healthy Volunteers Cardiovascular Diseases | Phase 1 | 2018-02-21 |
| Completed | S 81694 Plus Paclitaxel in Metastatic Breast Cancer Metastatic Breast Cancer, Metastatic Triple Negative Breast Cancer | Phase 1 / Phase 2 | 2018-01-04 |
| Active Not Recruiting | Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untre Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS) | Phase 3 | 2017-06-26 |
| Completed | Vascular Function and Biomarker Assessments in Healthy Volunteers and in Patients With Type 2 Diabetes Mellitu Type 2 Diabetes Mellitus | Phase 1 | 2017-04-03 |
| Completed | Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS) | Phase 1 | 2017-03-15 |
| Completed | Study of Efficacy and Safety of S 95005 (TAS-102) in Patients With Metastatic Colorectal Cancer Who Failed Sta Metastatic Colorectal Cancer | Phase 2 | 2017-03-03 |
| Completed | Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma | Phase 3 | 2017-02-20 |
| Completed | Efficacy and Safety Trial With S 44819 After Recent Ischemic Cerebral Event Post Stroke Recovery | Phase 2 | 2016-12-19 |
| Completed | A Study of Trifluridine/Tipiracil (Also Known as S 95005 or TAS-102) in Patients With a Pretreated Colorectal Metastatic Colorectal Cancer | Phase 3 | 2016-10-18 |
| Completed | Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leuka B-cell Acute Lymphoblastic Leukemia | Phase 1 | 2016-08-01 |
| Completed | Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed B-cell Acute Lymphoblastic Leukemia | Phase 1 | 2016-06-03 |
| Completed | Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer Metastatic Colorectal Cancer | Phase 1 | 2016-05-01 |
| Completed | A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untr Metastatic Colorectal Cancer | Phase 2 | 2016-04-29 |
| Completed | Phase II of BAX2398/5-FU/Calcium Levofolinate in Pancreatic Cancer Metastatic Pancreatic Cancer | Phase 2 | 2016-03-30 |
| Completed | Efficacy and Safety of S 47445 Versus Placebo as Adjunctive Treatment in Depressed Patients Not Fully Recovere Major Depressive Disorder | Phase 2 | 2016-03-01 |
| Active Not Recruiting | Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS) | Phase 1 | 2015-12-31 |
| Completed | Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 an Glioma | Phase 1 | 2015-06-01 |
| Completed | Efficacy and Safety of 3 Doses of S47445 Versus Placebo in Patients With Alzheimer's Disease at Mild to Modera Alzheimer's Disease | Phase 2 | 2015-02-01 |
| Completed | Dose-escalation Study of Oral Administration of S 055746 in Patients With Acute Myeloid Leukaemia or Myelodysp Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS) | Phase 1 | 2015-01-01 |
| Terminated | Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X) Chronic Uveitis | Phase 3 | 2014-08-01 |
| Completed | Dose-escalation Study of Oral Administration of S 55746 in Patients With Chronic Lymphocytic Leukaemia and B-C Chronic Lymphocytic Leukaemia (CLL), B-Cell Non-Hodgkin Lymphoma (NHL), Multiple Myeloma (MM) | Phase 1 | 2014-03-01 |
| Completed | Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mut Cholangiocarcinoma, Chondrosarcoma, Glioma | Phase 1 | 2014-03-01 |
| Recruiting | Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation Relapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies | Phase 1 | 2014-03-01 |
| Completed | A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor ( Breast Cancer | Phase 2 | 2013-12-01 |
| Terminated | Efficacy of Gevokizumab in the Treatment of Patients With Behçet's Disease Uveitis (EYEGUARD™-B) Behcet's Uveitis | Phase 3 | 2012-11-01 |
| Completed | Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors Solid Tumors | Phase 1 / Phase 2 | 2010-07-01 |
| Completed | Efficacy of Agomelatine in Patients With Obsessive-Compulsive Disorder Obsessive Compulsive Disorder | Phase 2 | 2010-05-01 |
| Completed | Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure Coronary Artery Disease | Phase 3 | 2009-09-01 |
| Completed | Effects of Ivabradine on Cardiovascular Events in Patients With Moderate to Severe Chronic Heart Failure and L Chronic Heart Failure | Phase 3 | 2006-09-01 |
| Completed | Efficacy and Safety of Ivabradine on Top of Atenolol in Stable Angina Pectoris Angina Pectoris | Phase 3 | 2005-06-01 |
| Terminated | Efficacy and Safety of S18986 in the Treatment of Mild Cognitive Impairment Patients Mild Cognitive Impairment | Phase 2 | 2005-06-01 |
| Completed | The BEAUTIFUL Study: Effects of Ivabradine in Patients With Stable Coronary Artery Disease and Left Ventricula Coronary Disease, Ventricular Dysfunction, Left | Phase 3 | 2004-12-01 |
| Completed | Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure Heart Failure, Congestive | Phase 2 | 2004-09-01 |
| Completed | S90652 in Paediatric Hypertension Hypertension | Phase 2 | 2003-11-01 |
| Completed | S90652 in Paediatric Hypertension Hypertension | Phase 2 | 2003-07-01 |